



## ERA-NET on Translational Cancer Research (TRANSCAN)

First Joint Transnational Call for Proposals (JTC 2011) on: "Validation of biomarkers for personalised cancer medicine"

### About

The ERA-NET on Translational Cancer Research (TRANSCAN) has been established under the ERA-NET scheme of the European Commission. The goal of the ERA-NET TRANSCAN is to coordinate the research efforts and funding programmes of European countries in the field of translational cancer research TRANSCAN

The first joint transnational call is launched on the topic: "Validation of biomarkers for personalised cancer medicine"

### Aim of the call

Transnational research proposals addressing the topic of the call must cover at least one of the following areas, which are equal in relevance for this call: prevention; early detection; diagnosis; prediction of response or resistance to treatment; prediction of treatment toxicity.

The research projects submitted within this call should fall into one of the following categories:

- bench to bed studies, stemming from previous laboratory and/or early phase clinical investigations;
- bed to bench studies, stemming from advanced clinical investigations.

In all cases, the research projects should clearly aim at the validation of previously identified candidate biomarkers or of their novel and/or combined use

### Mechanism of participation

Each transnational research consortium must involve a minimum of three and a maximum of seven research groups from at least three (3) different countries participating in the call (see list below). In addition, a research consortium must not include more than two research groups from the same country. Each research consortium must involve at least one basic or pre-clinical research team and at least one clinical team. A consortium may also involve other teams with specialised skills and know-how (biobanks, model systems, technological platforms, data management) or expertise (epidemiology, public health, ELSI, etc.). Each transnational consortium must nominate a coordinator from one of the JTC 2011 partner countries/regions. The maximum duration of the research project is 3 years.

Applicants must belong to one of the following categories:

- Academic research groups (from universities or other higher education or research institutions).
- Clinical/public health sector research groups (from hospitals/public health and/or other health care settings and health organisations).
- Enterprises (depending on national/regional eligibility rules), with particular emphasis on small and medium-sized enterprises.

### Application:

There will be a two-stage submission procedure using the electronic submission system of the Joint Call Secretariat (JTC 2011)

Pre-proposals (5 pages), deadline at VHIR: 10th February 2012

Full proposal: 5th June 2012

Participants eligibility

The Institute of Health Carlos III (ISCIII) will fund the following Spanish organizations:

-Hospitals, other health care settings as well as other public organisations with a health mission.

-A CIBER, just only if it is the consortium coordinator partner in a transnational project proposal

ISCIII will fund Up to 250,000 € if the Spanish Applicant is the TRANSCAN transnational project consortium coordinator.

ISCIII will fund up to 100,000 € if the Spanish Applicant is not the TRANSCAN transnational project consortium coordinator.

Spanish Institutions may submit different projects but each individual Spanish scientist can only submit one project.

Other funding agencies:

Austrian Science Fund (FWF), Austria

Research Foundation Flanders (FWO), Belgium

National Cancer Institute (INCa), France

Federal Ministry of Education and Research (BMBF), Germany

General Secretariat for Research and Technology, Ministry of Education, Life Long Learning and Religious Affairs (GSRT), Greece

Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel

Ministry of Health (MoH), Italy

Latvian Academy of Science (LAS), Latvia

National Research Fund (FNR), Luxembourg

National Centre for Research and Development (NCBiR), Poland

Institute of Oncology (IOB), Romania

Slovak Academy of Sciences (SAS), Slovakia

Ministry of Higher Education, Science and Technology (MHEST), Slovenia

Scientific and Technological Research Council of Turkey (TÜBİTAK), Turkey

.....